Microorganisms. 2020 Feb 5; 8 (2).Proposing BCG Vaccination for Mycobacterium avium ss. paratuberculosis (MAP) Associated Autoimmune Diseases

Bacille Calmette-Guerin (BCG) vaccination is widely practiced around the world to protect against the mycobacterial infection tuberculosis. BCG is also effective against the pathogenic mycobacteria that cause leprosy and Buruli’s ulcer. BCG is part of the standard of care for bladder cancer where, when given as an intravesicular irrigant, BCG acts as an immunomodulating agent and lessens the risk of recurrence. Mycobacterium avium ss. paratuberculosis (MAP) causes a fatal enteritis of ruminant animals and is the putative cause of Crohn’s disease of humans. MAP has been associated with an increasingly long list of inflammatory/autoimmune diseases: Crohn’s, sarcoidosis, Blau syndrome, Hashimoto’s thyroiditis, autoimmune diabetes (T1D), multiple sclerosis (MS), rheumatoid arthritis, lupus and Parkinson’s disease. Epidemiologic evidence points to BCG providing a “heterologous” protective effect on assorted autoimmune diseases; studies using BCG vaccination for T1D and MS have shown benefit in these diseases. This article proposes that the positive response to BCG in T1D and MS is due to a mitigating action of BCG upon MAP. Other autoimmune diseases, having a concomitant genetic risk for mycobacterial infection as well as cross-reacting antibodies against mycobacterial heat shock protein 65 (HSP65), could reasonably be considered to respond to BCG vaccination. The rare autoimmune disease, relapsing polychondritis, is one such disease and is offered as an example. Recent studies suggesting a protective role for BCG in Alzheimer’s disease are also explored. BCG-induced energy shift from oxidative phosphorylation to aerobic glycolysis provides the immunomodulating boost to the immune response and also mitigates mycobacterial infection-this cellular mechanism unifies the impact of BCG on the disparate diseases of this article

Solution to muscle wasting in aging

Excerpted from:

[**Biochemical Pharmacology**][Biochemical Pharmacology]

Available online 10 February 201


Aging is accompanied by progressive declines in skeletal muscle mass and strength and impaired regenerative capacity, predisposing older adults to debilitating age-related muscle deteriorations and severe morbidity. Muscle stem cells (muSCs) that proliferate, differentiate to fusion-competent myoblasts, and facilitate muscle regeneration are increasingly dysfunctional upon aging, impairing muscle recovery after injury. While regulators of muSC activity can offer novel therapeutics to improve recovery and reduce morbidity among aged adults, there are no known muSC regenerative small molecule therapeutics. We recently developed small molecule inhibitors of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed with aging in skeletal muscles and linked to impairment of the NAD\\+ salvage pathway, dysregulated sirtuin 1 activity, and increased muSC senescence. We hypothesized that NNMT inhibitor (NNMTi) treatment will rescue age-related deficits in muSC activity to promote superior regeneration post-injury in aging muscle. 24-month old mice were treated with saline (control), and low and high dose NNMTi (5 and 10 mg/kg) for 1-week post-injury, or control and high dose NNMTi for 3-weeks post-injury. All mice underwent an acute muscle injury (barium chloride injection) locally to the tibialis anterior (TA) muscle, and received 5-ethynyl-2’-deoxyuridine systemically to analyze muSC activity. *In vivo*contractile function measurements were conducted on the injured TA muscle and tissues collected for ex-vivo analyses, including myofiber cross-sectional area (CSA) measurements to assess muscle recovery. Results revealed that muscle stem cell proliferation and subsequent fusion were elevated in NNMTi-treated mice, supporting nearly 2-fold greater CSA and shifts in fiber size distribution to greater proportions of larger sized myofibers and fewer smaller sized fibers in NNMTi-treated mice compared to controls. Prolonged NNMTi treatment post-injury further augmented myofiber regeneration evinced by increasingly larger fiber CSA. Importantly, improved muSC activity translated not only to larger myofibers after injury but also to greater contractile function, with the peak torque of the TA increased by ∼70% in NNMTi-treated mice compared to controls. Similar results were recapitulated *in vitro* with C2C12 myoblasts, where NNMTi treatment promoted and enhanced myoblast differentiation with supporting changes in the cellular NAD\\+/NADH redox states. Taken together, these results provide the first clear evidence that NNMT inhibitors constitute a viable pharmacological approach to enhance aged muscle regeneration by rescuing muSC function, supporting the development of NNMTi as novel mechanism-of-action therapeutic to improve skeletal muscle regenerative capacity and functional recovery after musculoskeletal injury in older adults

[Biochemical Pharmacology]: https://www.sciencedirect.com/science/journal/00062952
[In Press_ Accepted]: https://www.sciencedirect.com/science/journal/aip/00062952
[What]: https://service.elsevier.com/app/answers/detail/a_id/22799/supporthub/sciencedirect/
[HarshiniNeelakantan]: https://www.sciencedirect.com/science/article/abs/pii/S0006295219300462?via%3Dihub#!
[https]: https://doi.org/10.1016/j.bcp.2019.02.008
[Get]: https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&contentID=S0006295219300462&orderBeanReset=true

Coronavirus Vaccination Campaign Urged

There is no question that in 3 months time we will have not one but several vaccines fid the new coronavirus virus outbreak. Several companies produced vaccines for SARS and at least one company for MERS. However, none of these efforts have resulted in a vaccine available to the public. This time it is abundantly clear that a vaccine should be made available vaccine to provide population wide herd immunity not only for this virus but also cross protection against future coronavirus outbreaks. I suggest a mass vaccination campaign sponsored by the government with a vaccine provided at cost.

Moderna and Invio biotechnology companies have been awarded contracts by different United states government agencies to develop a vaccine against the novel coronavirus (2019-nCoV) in Whuhan China.

China Quarantines 11 Million Residents Due To Coronavirus Outbreak

The United States recognizing the seriousness of the coronvirus outbreak has awarded contracts for the development of a vaccine. The quickest vaccine development platforms are the Mrna system of Moderna and the DNA vaccine system of Invio

The CDC describes both the nature of coronavirus and the outbreak in China as follows:

“Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases, says the CDC. Coronaviruses that infect animals can also evolve and become a human coronavirus. The best-known human coronaviruses are Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Outbreaks of a Novel Coronavirus (nCoV), now known as 2019-nCoV, are causing pneumonia-related infections in various counties in 2020

As of January 26, 2020, there are no approved antiviral medications to treat or vaccines to prevent the 2019-nCoV virus in the USA, says the Centers for Disease Control and Prevention (CDC).

2019-nCoV Outbreak

The WHO China Country Office was informed of cases of pneumonia of unknown etiology (cause) detected in Wuhan City, Hubei Province of China on December 31, 2019. A novel coronavirus (2019-nCoV) was identified as the causative virus by Chinese authorities”

The WHO has declared a country wide emergency in China and is monitoring the situation regarding the need for a pandemic world wide emergency should the virus spread within other countries.

European Journal of Cancer Prevention. 2018 Jul; 27 (4) : 303-309.Yellow fever vaccine 17D administered to healthy women aged between 40 and 54 years halves breast cancer risk: an observational study

Transcripts of human endogenous retrovirus K are expressed in most breast cancers (BCs). Yellow fever vaccine 17D (YFV) expresses a protein with a closely homologous epitope. Cross-reactive immunity could hypothetically inhibit BC growth at least in women aged around 50 years at diagnosis, in whom the prognosis of BC was found to be better than that in women younger or older. A cohort of 12 804 women who received YFV in the Veneto Region, Italy, was divided into two subcohorts according to age at vaccination and followed up through the Veneto Tumor Registry. The time since vaccination until cancer incidence was categorized (≤1.9; 2-3.9; 4-5.9; 6-7.9; 8-10.9; ≥11 years) and, using the lowest class as a reference, the incidence rate ratio for BC with a 95% confidence interval and P-value was estimated by Poisson regression in each time since vaccination class, adjusting for age and calendar period. In 3140 women vaccinated at 40-54 years of age, YFV administration resulted in a protective effect of long duration slowly fading over time with a U-shaped pattern of response. Overall, BC risk was reduced by about 50% (incidence rate ratio=0.46; 95% confidence interval=0.26-0.83; P=0.009) 2 years after vaccination. Cross-reactive antigens could not be the mechanism because no protection was observed in women vaccinated before 40 or after 54 years of age. BC cells in a microscopic stage of disease can be destroyed or severely damaged by YFV if BC is not very aggressive. To prove that treatment is truly effective, a placebo-controlled double-blind trial should be conducted.

African Swine Fever World Wide Outbreak May Preface a Human Pandemic Flu

There is currently an epidemic of African Swine Fever and since influenza virus undergoes reassortment in pigs it is possible that a human influenza virus might emerge by this process which may contain the virulence of pig African Swine Flu. There is now a grave epidemic amongst pigs in China and elsewhere in the world. African Swine Flu virus is both virulent and hard to kill . Hence the current epidemic among pigs. Time will tell what this might mean for humans.

Cuba reports that the Men B vaccine protects against gonorrhoea. Similar results have previously been reported from New Zealand as well.

Neisseria meningitidis and Neisseria gonorrhoeae share between 80% and 90% of their genetic sequence. Meningococcal serogroup B vaccines based on outer membrane vesicles-such as VA-MENGOC-BC-could cross-protect against gonorrhea. The aim of this study was to analyze the incidence rates of gonorrhea and other sexually transmitted diseases with respect to the use of the VA-MENGOC-BC vaccine.

Health statistics between 1970 and 2017 were reviewed and the incidence of meningococcal disease and sexually transmitted diseases (gonorrhea, syphilis, condyloma acuminatum , hepatitis B and human immunodeficiency virus infection) were analyzed during the pre- and post-vaccination periods.

Gonorrhea incidence was also analyzed by age groups. Results: VA-MENGOC-BC was successfully used to control a meningococcal epidemic in Cuba. The strategy to combat the epidemic was carried out in two stages. The first one was a nationwide mass-vaccination campaign from 1989 to 1990, targeting the population at highest-risk aged 3 months to 24 years. During the second stage, begun in 1991, it was included in the Expanded Immunization Program. Gonorrhea incidence increased from 1970 to 1989. However, after the VA-MENGOC-BC massive vaccination campaign a sharp decrease of gonorrhea incidence was observed. It lasted between 1989 and 1993. A second incidence peak was detected in 1995, but it dropped again. Data clearly show a decline in the incidence of gonorrhea following massive vaccination, in contrast with other sexually transmitted diseases. Incidence rates in unvaccinated age groups also decreased, probably due to herd immunity. Conclusion: There is evidence that VA-MENGOC-BC could induce a moderate protection against gonorrhea.

See Clinical and Experimental Vaccine Research. 2019 Jul; 8 (2) : 110-115.

A meningococcal B vaccine induces cross-protection against gonorrhea.

Rolando Felipe Ochoa Azze

PMID: 31406692

Interesting article excerpted below on vaccination causing flare ups in gout patients.

Vaccination may increase gout flare risk

medwireNews: The increased risk for gout flares following receipt of the aluminum-free recombinant zoster vaccine (RZV) is not unique to this vaccine but is instead associated with vaccination in general, regardless of the adjuvant used, US researchers report.

However, Hyon Choi (Massachusetts General Hospital, Boston) and colleagues stress that “the absolute magnitude of increased odds of gout flares with vaccinations remains small.”

The researchers explain that although RZV is “the preferred zoster vaccine endorsed by the Advisory Committee on Immunization Practices,” two phase III clinical trials have shown that it is associated with a 3.6-fold increased risk for gout flares, prompting the implementation of an enhanced post marketing surveillance program.

An Old Vaccine Keeps Getting Better — From: Precision Vaccinations

An Old Vaccine Keeps Getting Better

Bacille Calmette-Guerin (BCG) vaccine enhances bacteria protection and appears to last longer

July 22nd, 2019 – New research about an old vaccine showed once again how effective it is, but also suggests the Bacille Calmette-Guerin (BCG) vaccine improves our immune response to a wider range of bacteria than originally intended.

A new study published on July 12, 2019, by the University of Otago, Wellington, found the BCG vaccine, which has been in use since 1921, gave stronger protection and appeared to last far longer than previously thought.

Previous studies have given widely different results on the effectiveness of BCG and its effectiveness had been questioned in the past, said Principal investigator Dr. Ayesha Verrall, who is also an infectious diseases physician at Wellington Hospital, in a press release.

“Our research has shown that the people who remained uninfected were truly immune, and not just lucky and uninfected. This is also supported by the fact they have stronger innate immune

“We also found this protection was associated with stronger innate immune responses to a range of different bacteria, suggesting BCG protects people by ‘training’ their innate immune cells.”

“This is different from how vaccines are conventionally thought to work, through inducing memory cells to make antibodies that are highly specific to a particular bacteria.”

“Our finding that the BCG vaccine appears to work through the innate immune system is consistent with it having broader benefits than just TB protection. These non-specific effects are really interesting and need further study.”

According to the World Health Organization, approximately 1.7 billion people—23 percent of the world’s population—have latent TB infection and carry the risk of developing TB during their lifetime.

Tuberlucious vaccines

The BCG vaccine is not widely used in the United States, but it is often given to infants and small children in other countries where TB is common, says the US Centers for Disease Control and Prevention (CDC).

In the United States, BCG should be considered for only very select people who meet specific criteria and in consultation with a TB expert. Healthcare providers who are considering BCG vaccination for their patients are encouraged to discuss this intervention with the TB control program in their area.

In the USA, the BCG vaccination should only be considered for children who have a negative TB test and who are continually exposed and cannot be separated from adults who:

Are untreated or ineffectively treated for TB disease, and the child cannot be given long-term primary preventive treatment for TB infection; or

Have TB disease caused by strains resistant to isoniazid and rifampin.

Future tuberculosis vaccines would ideally target both M. tuberculosis-infected and uninfected adolescents and adults said these researchers.

Dr. Verrall is about to start a new field study to see if BCG vaccination works by adding chemical marks to innate immune cells’ DNA, leading to a “boost” for innate immune responses. This new work is funded by the New Zealand Health Research Council.

The research was part of a long-standing collaboration on TB between the University of Otago’s Centre for International Health, Universitas Padjadjaran, and Radboud University.